Page last updated: 2024-11-08

methandriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methandriol: A synthetic steroid with anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID229021
CHEMBL ID1079446
CHEBI ID34834
SCHEMBL ID329841
MeSH IDM0013553

Synonyms (102)

Synonym
unii-5730z864kg
5-andriodiol
5730z864kg ,
methandriolum
androst-5-ene-3,17-diol, 17-methyl-, (3-beta,17-beta)
stenibell
17-methylandrost-5-ene-3-beta,17-beta-diol
methandriol [inn]
metandriol [inn-spanish]
nsc 22366
einecs 208-301-0
methylandrostendiolum
17alpha-methylandrostenediol
17alpha-methyl-androst-5-ene-3beta,17beta-diol
androst-5-ene-3,17-diol, 17-methyl-, (3beta,17beta)
17alpha-methylandrost-5-ene-3beta,17beta-diol
methandriolum [inn-latin]
androst-5-ene-3,17-diol, 17-methyl-, (3beta,17beta)-
androst-5-ene-3beta,17beta-diol, 17-methyl-
androst-5-ene-3-beta,17-beta-diol, 17-methyl-
17alpha-methyl-3beta,17beta-dihydroxyandrosten-5
(3s,8r,9s,10r,13s,14s,17s)-10,13,17-trimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,17-diol
androdiol
cenabolic
madiol
stenibel
neosteron
androtestone-m
diolandrone
metandiol
stenediol
nabadial
hibol
notandron
methostan
metocryst
neutrosteron
esjaydiol
metildiolo
metandriol
stenosterone
methanabol
diolostene
neostene
masdiol
testodiol
androst-5-ene-3.beta., 17-methyl-
androst-5-ene-3, 17-methyl-, (3.beta.,17.beta.)
metidione
metendiol
androteston-m
methylandrostendiol
methandrolan
neutrormone
notandron-depot
protandren
methandriol
methandrioldiol
nsc-22366
mestenediol
androst-5-ene-3, 17-methyl-, (3.beta.,17.beta.)-
troformone
methylandrostenediol
nsc22366
crestabolic
521-10-8
17alpha-methyl-5-androstene-3beta,17beta-diol
LMST02020012
MLS001424095
MLS000759415
smr000466310
HMS2051L13
methandriol (inn)
D08196
orabol [veterinary] (tn)
M0146
sinesex
orabol
chebi:34834 ,
CHEMBL1079446
HMS2234K15
CCG-100956
methandriol [vandf]
methandriol [who-dd]
17.alpha.-methylandrost-5-ene-3.beta.,17.beta.-diol
methandriol [mart.]
methandriol [mi]
SCHEMBL329841
NC00206
WRWBCPJQPDHXTJ-DTMQFJJTSA-N
CS-7834
17-methylandrost-5-ene-3.beta.,17.beta.-diol
17.alpha.-methylandrost-5-ene-3,17-diol-, (3.beta.,17.beta.)-
androst-5-ene-3,17-diol, 17-methyl-, (.beta.,.beta.,.alpha.)-
androst-5-ene-3.beta.,17.beta.-diol, 17-methyl-
17.alpha.-methyl-5-androsten-3.beta.,17.beta.-diol
androst-5-ene-3,17-diol, 17-methyl-, (3.beta.,17.beta.)-
AKOS030573835
HY-103585
(3s,8r,10r,13s,17s)-10,13,17-trimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol
DTXSID50878534
methylandrostenediol 100 microg/ml in acetonitrile

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A 4-fold increase in dosage caused marked suppression of basal LH, the LH surge, and GnRH-induced LH release."( Effect of prolonged administration of anabolic and androgenic steroids on reproductive function in the mare.
Irvine, CH; Turner, JE, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID468152Neuroprotective activity in rat PC12 cells assessed as inhibition of serum deprivation-induced apoptosis after 24 hrs by APO Percentage apoptosis assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (125)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990119 (95.20)18.7374
1990's2 (1.60)18.2507
2000's3 (2.40)29.6817
2010's1 (0.80)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.27 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index50.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.41%)5.53%
Reviews2 (1.41%)6.00%
Case Studies1 (0.70%)4.05%
Observational0 (0.00%)0.25%
Other137 (96.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]